KNC Laboratories Co.,Ltd. (JP:6568)

:6568

6568

KNC Laboratories Co.,Ltd.

RESEARCH TOOLSreports

KNC Laboratories Co.,Ltd. (6568) Price & Analysis

Compare

0 Followers

6568 Stock Chart & Stats

¥1124.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥1124.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥957.00 - ¥1,418.00

Previous CloseN/A

Volume3.20K

Average Volume (3M)2.89K

Market Cap

¥9.90B

Enterprise Value¥9.11B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)20.8

Beta0.54

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.98%

Share Statistics

EPS (TTM)13.53

Shares Outstanding7,779,900

10 Day Avg. Volume3,150

30 Day Avg. Volume2,890

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)0.62

Price to Sales (P/S)1.02

P/FCF Ratio-4.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet (high Equity, Low Leverage)A consistently high equity ratio (>65%) and low debt-to-equity provide durable financial flexibility. This reduces refinancing risk, supports investment or downturn absorption, and preserves credit options, enabling the company to pursue strategic initiatives over the next 2–6 months.

High Operating Cash ConversionStrong conversion of net income into operating cash flow indicates quality earnings and reliable internal cash generation. This supports working capital needs and ongoing operations, reducing near-term financing reliance and strengthening the firm's ability to fund projects or service obligations.

Historical Revenue Growth With Stable Gross MarginsA multi-year revenue increase through 2024 combined with relatively stable gross margins suggests structural demand and resilient cost control at the COGS level. That track record supports recovery potential after short-term dips and underpins longer-term revenue and margin stability.

Bears Say

Recent Revenue And EPS DeteriorationA year-over-year revenue decline in 2025 alongside a ~59% drop in EPS signals weakening top-line momentum and pressure on profitability. If these trends persist they will constrain retained earnings, reduce reinvestment capacity, and raise execution risk for growth initiatives over the medium term.

Negative Free Cash Flow Driven By High CapexSustained negative free cash flow from elevated capital spending can erode liquidity and compel external financing. If capex does not quickly translate into higher returns, the company may face constrained financial flexibility, limiting dividends, share buybacks, or opportunistic investments.

Pressure On Profitability (EBIT And Net Margins Dipped)A decline in operating and net margins suggests cost inflation, pricing pressure, or mix shifts reducing earnings power. Persistent margin compression undermines returns on capital and weakens the company’s ability to fund growth organically, requiring structural cost or pricing remedies.

6568 FAQ

What was KNC Laboratories Co.,Ltd.’s price range in the past 12 months?

KNC Laboratories Co.,Ltd. lowest stock price was ¥957.00 and its highest was ¥1418.00 in the past 12 months.

What is KNC Laboratories Co.,Ltd.’s market cap?

KNC Laboratories Co.,Ltd.’s market cap is ¥9.90B.

When is KNC Laboratories Co.,Ltd.’s upcoming earnings report date?

KNC Laboratories Co.,Ltd.’s upcoming earnings report date is May 19, 2026 which is in 52 days.

How were KNC Laboratories Co.,Ltd.’s earnings last quarter?

KNC Laboratories Co.,Ltd. released its earnings results on Feb 13, 2026. The company reported ¥13.53 earnings per share for the quarter, beating the consensus estimate of N/A by ¥13.53.

Is KNC Laboratories Co.,Ltd. overvalued?

According to Wall Street analysts KNC Laboratories Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KNC Laboratories Co.,Ltd. pay dividends?

KNC Laboratories Co.,Ltd. pays a Semiannually dividend of ¥17 which represents an annual dividend yield of 2.98%. See more information on KNC Laboratories Co.,Ltd. dividends here

What is KNC Laboratories Co.,Ltd.’s EPS estimate?

KNC Laboratories Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KNC Laboratories Co.,Ltd. have?

KNC Laboratories Co.,Ltd. has 7,779,900 shares outstanding.

What happened to KNC Laboratories Co.,Ltd.’s price movement after its last earnings report?

KNC Laboratories Co.,Ltd. reported an EPS of ¥13.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.556%.

Which hedge fund is a major shareholder of KNC Laboratories Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:6568

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KNC Laboratories Co.,Ltd.

KNC Laboratories Co., Ltd. engages in the research, development, and production solutions of organic chemicals in Japan. The company offers products for use in the pharmaceutical, electronic-chemical, agrochemical, energy, and environment fields. It offers support services for drugs and functional chemicals. The company was incorporated in 1985 and is headquartered in Kobe, Japan.